A Randomized Double-Blind Parallel Placebo-Controlled Study of the Efficacy Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis

Brief Description Of Study

This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group, proof-of-concept study. The primary purpose of this study is to evaluate the effect of dupilumab on relieving EoE clinical symptoms and reducing esophageal inflammation in adults. Currently there is no regulatory-approved endpoint for drug registration for this indication. Published clinical trials in EoE treatment with swallowed topical corticosteroids measured clinical responses and histological changes (Alexander 2012, Dellon 2012, Straumann 2010). However, emerging data show that there does not appear to be a correlation between histology changes, such as reduction in eosinophil counts, and clinical symptoms. Collaborative efforts by the international Eosinophilic Esophagitis Activity Index (EEsAI) study group with the Food and Drug Administration (FDA) are ongoing in developing and validating clinically meaningful endpoints, such as patient-reported outcome (PRO), for evaluating efficacy for approval of treatment for EoE (Fiorentino 2012). Therefore, efficacy in this study will be assessed based on clinical signs and symptoms using the EoE-specific PROs currently in development, as well as on anatomical and histological findings from esophagogastroscopy with biopsies.

Clinical Study Identifier: 821884

Contact research investigator to learn more about this study by filling out the form
below.

Your Email:

Not a valid e-mail address

Please Provide Email Address

Your Name:

First name is mandatory

Your Phone Number:

Please provide phone number

Invalid phone number

Valid phone number

Send copy of this to me

To:

Research Study Investigator

Subject:

I am interested in participating in your Research Study

Dear Investigator,
I'm interested in learning more about and participating in your research study
named: A Randomized Double-Blind Parallel Placebo-Controlled Study of the Efficacy Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.